Recurrence of bacteremia and infective endocarditis according to bacterial species of index endocarditis episode

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,05 MB, PDF-dokument

Purpose: In patients surviving infective endocarditis (IE) recurrence of bacteremia or IE is feared. However, knowledge is sparse on the incidence and risk factors for the recurrence of bacteremia or IE. Methods: Using Danish nationwide registries (2010–2020), we identified patients with first-time IE which were categorized by bacterial species (Staphylococcus aureus, Enterococcus spp., Streptococcus spp., coagulase-negative staphylococci [CoNS], ‘Other’ microbiological etiology). Recurrence of bacteremia (including IE episodes) or IE with the same bacterial species was estimated at 12 months and 5 years, considering death as a competing risk. Cox regression models were used to compute adjusted hazard ratios of the recurrence of bacteremia or IE. Results: We identified 4086 patients with IE; 1374 (33.6%) with S. aureus, 813 (19.9%) with Enterococcus spp., 1366 (33.4%) with Streptococcus spp., 284 (7.0%) with CoNS, and 249 (6.1%) with ‘Other’. The overall 12-month incidence of recurrent bacteremia with the same bacterial species was 4.8% and 2.6% with an accompanying IE diagnosis, while this was 7.7% and 4.0%, respectively, with 5 years of follow-up. S. aureus, Enterococcus spp., CoNS, chronic renal failure, and liver disease were associated with an increased rate of recurrent bacteremia or IE with the same bacterial species. Conclusion: Recurrent bacteremia with the same bacterial species within 12 months, occurred in almost 5% and 2.6% for recurrent IE. S. aureus, Enterococcus spp., and CoNS were associated with recurrent infections with the same bacterial species.

OriginalsprogEngelsk
TidsskriftInfection
Vol/bind51
Sider (fra-til)1739–1747
ISSN0300-8126
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Lauge Østergaard: has received an independent research grant from the Novo Nordisk Foundation (NNF23OC0081668) related to mitral valve regurgitation. Marianne Voldstedlund: has received a grant from the Novo Nordisk Foundation (NNF20OC0063177) not related to this work; lecture fee from MyLab Oy, Finland. Niels Eske Bruun: has received investigator-initiated grants from: The Novo Nordisk Foundation, The Augustinus Foundation, The Kaj Hansen Foundation, and Health Insurance Denmark, not related to this study. Henning Bundgaard: has received lecture fees from Bristol Myers Squibb, Sanofi, MSD and Amgen. Kasper Iversen: None. Mia Marie Pries-Heje: None. Katra Hadji -Turdeghal: None. Peter Graversen: None. Claus Moser: Supported by the Novo Nordisk Foundation—“Borregaard Clinical Scientist Grant” (Grant no. NNF17OC0025074). Christian Østergaard Andersen: None. Kirstine Kobberøe Søgaard: None. Lars Køber: Speaker’s honorarium from Novo, Novartis, AstraZeneca, Boehringer and Bayer. Emil Loldrup Fosbøl: Novo Nordisk Foundation and the Danish Heart Association: Independent research grant related to valvular heart disease and endocarditis.

Publisher Copyright:
© 2023, The Author(s).

ID: 362696461